Abstract
Objective: The primary focus of this review is to highlight the current and emerging proinflammatory role of MK2 kinase signaling in p38MAPK pathway and to provide a detailed evaluation on the prospects of MK2 inhibition with special emphasis on the etiology of chronic inflammatory airway diseases, such as asthma, idiopathic pulmonary fibrosis, lung cancer, acute lung injury and acute respiratory distress syndrome.
Background: MK2 belongs to serine-threonine kinase family and is activated directly by stress and inflammatory signal through p38MAPK phosphorylation in diverse inflammatory conditions through the Toll-like receptor signaling pathway. MK2 has been thought to be a critical factor involved in the regulation of synthesis and release of pro-inflammatory (TNF-α, IL-6 and IL-1β, etc.) proteins. Targeted inhibition of MK2 kinase has been shown to significantly reduce the production and release of these cytokine molecules. Therefore, MK2 has been identified as an effective strategy (alternative to p38MAPK) to block this pro-inflammatory signaling pathway.
Results: The inhibition of MK2 may lead to similar or better efficacy as that of p38 inhibitors, and interestingly avoids the systemic toxicity shown by the p38 inhibitors. Thus, MK2 has been the focus of intense interdisciplinary research and its specific inhibition can be a novel and potential therapeutic strategy for the treatment of chronic airway inflammatory diseases.
Conclusion: Promising advancement in understanding and rigorous exploration of the role of MK2 kinase in inflammatory processes may contribute to the development of newer and safer therapy for the treatment of chronic airway inflammatory diseases in the future.
Keywords: Mitogen-activated protein kinase-activated protein kinase-2 (MAPKAPK2 or MK2), inflammation, inflammatory airway disease, p38MAPK pathway, chronic lung inflammation, MK2 inhibitors, asthma.
Graphical Abstract
[1]
Fiore M, Forli S, Manetti F. Targeting mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2, MK2): Medicinal chemistry efforts to lead small molecule inhibitors to clinical trials. J Med Chem 2016; 59(8): 3609-34.
[2]
Xing L. Clinical candidates of small molecule p38 MAPK inhibitors for inflammatory diseases. MAP Kinase 2015; 4: 5508-14.
[3]
Moens U, Kostenko S, Sveinbjornsson B. The role of mitogen activated protein kinase-activated protein kinases (MAPKAPKs) in inflammation. Genes 2013; 4: 101-33.
[4]
Gaestel M. What goes up must come down: Molecular basis of MAPKAP kinase 2/3-dependent regulation of the inflammatory response and its inhibition. Biol Chem 2013; 394: 1301-15.
[5]
Edmunds JJ, Talanian RV. MAPKAP kinase 2 as a target for anti-inflammatory drug discovery. London: The Royal Society of Chemistry 2012.
[6]
Ehlting C, Ronkina N, Bohmer O, et al. Distinct Functions of the Mitogen-activated Protein Kinase-activated Protein (MAPKAP) Kinases MK2 and MK3. J Biol Chem 2011; 286(27): 24113-24.
[7]
Hammaker D, Firestein GS. “Go upstream, young man”: Lessons learned from the p38 saga. Ann Rheum Dis 2010; 69(S1): i77-82.
[8]
Goldstein DM, Kuglstatter A, Lou Y, Soth MJ. Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J Med Chem 2010; 53: 2345-53.
[9]
Karcher SC, Laufer SA. Successful structure-based design of recent p38 MAP kinase inhibitors. Curr Top Med Chem 2009; 9: 655-76.
[11]
Coulthard LR, White DE, Jones DL, McDermott MF, Burchill SA. p38(MAPK): Stress responses from molecular mechanisms to therapeutics. Trends Mol Med 2009; 15: 369-79.
[12]
Cohen P. Targeting protein kinases for the development of anti-inflammatory drugs. Curr Opin Cell Biol 2009; 21: 317-24.
[13]
Peifer C, Wagner G, Laufer S. New approaches to the treatment of infl ammatory disorders small molecule inhibitors of p38MAP kinase. Curr Top Med Chem 2006; 6(2): 113-9.
[14]
Lee MR, Dominguez C. MAP Kinase p38 Inhibitors: Clinical results and an intimate look at their interactions with p38 protein. Curr Med Chem 2005; 12: 2979-94.
[15]
Jr JH, Leftheri K. Small molecule p38 inhibitors: Novel structural features and advances from 2002–2005. Curr Top Med Chem 2005; 5: 967-85.
[16]
Diller DJ, Lin TH, Metzger A. The discovery of novel chemotypes of p38 kinase inhibitors. Curr Top Med Chem 2005; 5: 953-65.
[17]
Saklatvala J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol 2004; 4(4): 372-7.
[18]
Chopra P, Kanoje V, Semwal A, Ray A. Therapeutic potential of inhaled p38 mitogen-activated protein kinase inhibitors for inflammatory pulmonary diseases. Expert Opin Investig Drugs 2008; 17(10): 1411-25.
[19]
Dominguez C, Powers DA, Tamayo N. p38 MAP kinase inhibitors: Many are made, but few are chosen. Curr Opin Drug Discov 2005; 8: 421-30.
[20]
Dambach DM. Potential adverse effects associated with inhibition of p38 α/β MAPkinases. Curr Top Med Chem 2005; 5(10): 929-39.
[21]
Allen M, Svensson L, Roach M, Hambor J, McNeish J, Gabel CA. Deficiency of the stress kinase p38 results in embryonic lethality: characterization of the kinase dependence of stress responses of enzyme defi cient embryonic stem cells. J Exp Med 2000; 191: 859-70.
[22]
Lee JC, Kassis S, Kumar S, Badger A, Adams JL. p38 mitogen-activated protein kinase inhibitors-mechanisms and therapeutic potentials. Pharmacol Ther 1999; 82(2-3): 389-97.
[23]
Clement SL, Scheckel C, Stoecklin G, Andersen JL. Phosphorylation of tristetraprolin by MK2 impairs AU-rich element mRNA decay by preventing deadenylase recruitment. Mol Cell Biol 2011; 31(2): 256-66.
[24]
Fyhrquist N, Matikainen S, Lauerma A. MK2 signaling: Lessons on tissue specificity in modulation of inflammation. J Invest Dermatol 2010; 130: 342-4.
[25]
Duraisamy S, Bajpai M, Bughani U, Dastidar SG, Ray A, Chopra P. MK2: A novel molecular target for anti-inflammatory therapy. Expert Opin Ther Targets 2008; 12(8): 921-36.
[26]
Vandendriessche B, Goethals A, Simats A, Hamme EV, Brouckaert P, Cauwels A. MAPK-activated protein kinase 2-deficiency causes hyperacute tumor necrosis factor-induced inflammatory shock. BMC Physiol 2014; 14(1): 1-10.
[27]
Ronkina N, Menon MB, Schwermann J, et al. MAPKAP kinases MK2 and MK3 in inflammation: Complex regulation of TNF biosynthesis via expression and phosphorylation of tristetraprolin. Biochem Pharmacol 2010; 80: 1915-20.
[28]
Hegen M, Gaestel M, Nickerson-Nutter CL, Lin LL, Telliez JB. MAPKAP kinase 2-deficient mice are resistant to collagen-induced arthritis. J Immunol 2006; 177: 1913-7.
[29]
Lehner MD, Schwoebel F, Kotlyarov A. Mitogen-activated protein kinase-activated protein kinase 2-deficient mice show increased susceptibility to Listeria monocytogenes infection. J Immunol 2002; 168(9): 4667-73.
[30]
Kotlyarov A, Gaestel M. Is MK2 (mitogen-activated protein kinase-activated protein kinase 2) the key for understanding post-transcriptional regulation of gene expression? Biochem Soc Trans 2002; 30(6): 959-63.
[31]
Kotlyarov A, Neininger A, Schubert C, et al. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat Cell Biol 1999; 1: 94-7.
[32]
Singh R, Diwan M, Dastidar S, Najmi A. Differential effect of p38 and MK2 kinase inhibitors on the inflammatory and toxicity biomarkers in vitro. Hum Exp Toxicol 2018; 37(5): 521-31.
[33]
Singh RK, Najmi AK, Dastidar SG. Biological functions and role of mitogen-activated protein kinase activated protein kinase 2 (MK2) in inflammatory diseases. Pharmacol Rep 2017; 69: 746-56.
[34]
Khorasanizadeh M, Eskian M, Gelfand EW, Rezaei N. Mitogen-activated protein kinases as therapeutic targets for asthma. Pharmacol Ther 2017; 174: 112-26.
[35]
Wu T, Shi J-X, Geng S, Zhou W, Shi Y, Su X. The MK2/HuR signaling pathway regulates TNF-α-induced ICAM-1 expression by promoting the stabilization of ICAM-1 mRNA. BMC Pulm Med 2016; 16: 84-94.
[36]
Qian F, Deng J, Wang G, Ye RD, Christman JW. Pivotal Role of mitogen-activated protein kinase-activated protein kinase 2 in inflammatory pulmonary diseases. Curr Protein Pept Sci 2016; 17(4): 332-42.
[37]
Chupp G, Yan X, Nezgovorova V, et al. MAPKAP kinase 2(MK2) expression is associated with severe asthma. Eur Respir J 2016; 48(60): PA4649.
[38]
Vittal R, Fisher A, Gu H, et al. Peptide-Mediated inhibition of mitogen-activated protein kinase–activated protein kinase–2 ameliorates bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2013; 49(1): 47-57.
[39]
Loomis-King H, Flaherty KR, Moore BB. Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis. Curr Opin Pharmacol 2013; 13(3): 377-85.
[40]
Su X, Ao L, Zou N, et al. Post-transcriptional regulation of TNF-induced expression of ICAM-1 and IL-8 in human lung microvascular endothelial cells: An obligatory role for the p38 MAPK-MK2 pathway dissociated with HSP27. BBA-Mol Cell Res 2008; 1783(9): 1623-31.
[41]
Greenberg AK, Basu S, Hu J, et al. Selective p38 activation in human non-small cell lung cancer. Am J Respir Cell Mol Biol 2002; 26(5): 558-64.
[43]
Jackson EL, Olive KP, Tuveson DA, et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 2005; 65(22): 10280-8.
[44]
Damarla M, Hasan E, Boueiz A, et al. Mitogen activated protein kinase activated protein kinase 2 regulates actin polymerization and vascular leak in ventilator associated lung injury. PLoS One 2009; 4(2): e4600.
[45]
Damarla M, Parniani AR, Johnston L, et al. Mitogen-activated protein kinase-activated protein kinase 2 mediates apoptosis during lung vascular permeability by regulating movement of cleaved caspase 3. Am J Respir Cell Mol Biol 2014; 50(5): 932-41.
[46]
Kayyali US, Pennella CM, Trujillo C, Villa O, Gaestel M, Hassoun PM. Cytoskeletal changes in hypoxic pulmonary endothelial cells are dependent on MAPK-activated protein kinase MK2. J Biol Chem 2002; 277(45): 42596-602.
[47]
Meng W, Swenson LL, Fitzgibbon MJ, et al. Structure of Mitogen-Activated Protein Kinase-Activated Protein (MAPKAP) kinase 2 suggests a bifunctional switch that couples kinase activation with nuclear export. J Biol Chem 2002; 277: 37401-5.
[48]
Neininger A, Thielemann H, Gaestel M. FRET-based detection of different conformations of MK2. EMBO Rep 2001; 2: 703-8.
[49]
Ben-Levy R, Hooper S, Wilson R, Paterson HF, Marshall CJ. Nuclear export of the stress-activated protein kinase p38 mediated by its substrate MAPKAP kinase-2. Curr Biol 1998; 8: 1049-57.
[50]
Ben-Levy R, Leighton IA, Doza YN, et al. Identification of novel phosphorylation sites required for activation of MAPKAP kinase-2. EMBO J 1995; 14: 5920-30.
[51]
White A, Pargellis CA, Studts JM, Werneburg BG, Farmer BT. Molecular basis of MAPK-activated protein kinase 2: p38 assembly. Proc Natl Acad Sci USA 2007; 104: 6353-8.
[52]
Natesan S, Subramaniam R, Bergeron C, Balaz S. Binding affinity prediction for ligands and receptors forming tautomers and ionization species: inhibition of mitogen-activated protein kinase activated protein kinase 2 (MK2). J Med Chem 2012; 55: 2035-47.
[53]
Underwood KW, Parris KD, Federico E, et al. Catalytically active MAPKAP kinase 2 structures in complex with staurosporine and ADP reveal differences with the autoinhibited enzyme. Structure 2003; 11: 627-36.
[54]
Kotlyarov A, Yannoni Y, Fritz S, et al. Distinct cellular functions of MK2. Mol Cell Biol 2002; 22(13): 4827-35.
[55]
Ronkina N, Kotlyarov A, Gaestel M. MK2 and MK3-a pair of isoenzymes? Front Biosci 2008; 13: 5511-21.
[56]
Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev 2011; 75: 50-83.
[57]
Gaestel M. MAPKAP kinases-MKs-two’s company, three’s a crowd. Nat Rev Mol Cell Biol 2006; 7: 120-30.
[58]
Stoecklin G, Stubbs T, Kedersha N, et al. MK2-induced tristetraprolin:14-3-3 complexes prevent stress granule association and ARE-mRNA decay. EMBO J 2004; 23: 1313-24.
[59]
Arthur JSC, Ley SC. Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol 2013; 13: 679-92.
[60]
Blink BVd, Juffermans NP, Hove Tt, et al. P38 Mitogen-activated
protein kinase inhibition increases cytokine release by macrophages
in vitro and during infection in vivo.. J Immunol 2001; 166:
582-7.
[61]
Branger J. Anti-Inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol 2002; 168: 4070-7.
[62]
Cheung PC, Campbell DG, Nebreda AR, Cohen P. Feedback control of the protein kinase TAK1 by SAPK2a/p38α. EMBO J 2003; 22: 5793-805.
[63]
Dobreva ZG, Miteva LD, Stanilova SA. The inhibition of JNK and p38 MAPKs downregulates IL-10 and differentially affects c-Jun gene expression in human monocytes. Immunopharmacol Immunotoxicol 2009; 31(2): 195-201.
[64]
Pettus LH, Wurz RP. Small-molecule p38 MAP kinase inhibitors for the treatment of inflammatory diseases: Novel structures and developments during 2006-2008. Curr Top Med Chem 2008; 8: 1452-67.
[65]
Regan J, Breitfelder S, Cirillo P, et al. Pyrazole urea-based inhibitors of p38 MAP kinase: From lead compound to clinical candidate. J Med Chem 2002; 45: 2994-3008.
[66]
Ryoo S, Choi J, Kim J, et al. BIRB 796 has distinctive anti-inflammatory effects on different cell types. Immune Netw 2013; 13(6): 283-8.
[67]
Wilson KP, McCaffrey PG, Hsiao K, et al. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem Biol 1997; 4: 423-31.
[68]
Zhang J, Shen B, Lin A. Novel strategies for inhibition of the p38 MAPK pathway. Trends Pharmacol Sci 2007; 28(6): 286-95.
[69]
Hale KK, Trollinger D, Rihanek M, Manthey CL. Differential expression and activation of p38 mitogen-activated protein kinase alpha, beta, gamma, and delta in inflammatory cell lineages. J Immunol 1999; 162: 4246-52.
[70]
Lee JC, Kumar S, Griswold DE, Underwood DC, Votta BJ, Adams JL. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacol 2000; 47: 185-201.
[71]
Natarajan SR, Doherty JB. P38 MAP kinase inhibitors: Evolution of imidazole based and pyrido-pyrimidin-2-one lead classes. Curr Top Med Chem 2005; 5: 987-1003.
[72]
Pargellis C, Regan J. Inhibitors of p38 mitogen-activated protein kinase for the treatment of rheumatoid arthritis. Curr Opin Investig Drugs 2003; 4(5): 566-71.
[73]
Goldstein DM, Gabriel T. Pathway to the clinic: Inhibition of P38 MAP Kinase. A review of ten chemotypes selected for development. Curr Top Med Chem 2005; 5: 1017-29.
[74]
Marber MS, Molkentin JD, Force T. Developing small molecules to inhibit kinases unkind to the heart: p38 MAPK as a case in point. Drug Discov Today Dis Mech 2010; 7(2): e123-7.
[76]
Muniyappa H, Das KC. Activation of c-Jun N-Terminal Kinase (JNK) by widely used specific p38 MAPK inhibitor SB202190 and SB203580: A MLK-3 MKK7-dependent mechanism. Cell Signal 2008; 20(4): 675-83.
[77]
Ananieva O, Darragh J, Johansen C, et al. The kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signaling. Nat Immunol 2008; 9(9): 1028-36.
[78]
Mudgett JS, Ding J, Guh-Siesel L. Essential role for p38 α mitogen-activated protein kinase in placental angiogenesis. Proc Natl Acad Sci USA 2000; 97(19): 10454-9.
[79]
Charron CE, Russell P, Ito K, et al. RV568, a narrow spectrum kinase inhibitor with p38MAPK-α and -γ selectivity, supresses COPD inflammation. Eur Respir J 2017; 50(4): 1700188.
[80]
Gurgis FMS, Ziaziaris W, Munoz L. Mitogen-activated protein kinase-activated protein kinase 2 in neuroinflammation, heat shock protein 27 phosphorylation, and cell cycle: Role and targeting. Mol Pharmacol 2014; 85: 345-56.
[81]
Ronkina N, Kotlyarov A, Dittrich-Breiholz O, et al. The Mitogen-Activated Protein Kinase (MAPK)-activated protein kinases MK2 and MK3 cooperate in stimulation of tumor necrosis factor biosynthesis and stabilization of p38 MAPK. Mol Cell Biol 2007; 27: 170-81.
[82]
Herlaar E, Brown Z. p38 MAPK signalling cascades in inflammatory disease. Mol Med Today 1999; 5: 439-47.
[83]
Kumar S, Boehm J, Lee JC. p38 MAP kinases: Key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003; (2): 9-14.
[84]
Gorska MM, Liang Q, Stafford SJ, et al. MK2 controls the level of negative feedback in the NF-kB pathway and is essential for vascular permeability and airway inflammation. J Exp Med 2007; 204: 1637-52.
[85]
Moretto N, Bertolini S, Iadicicco C, et al. Cigarette smoke and its component acrolein augment IL-8/CXCL8 mRNA stability via p38 MAPK/MK2 signaling in human pulmonary cells. Am J Physiol Lung Cell Mol Physiol 2012; 303: L929-38.
[86]
Steele MP, Schwartz DA. Molecular mechanisms in progressive idiopathic pulmonary fibrosis. Annu Rev Med 2013; 64: 265-76.
[87]
Kage H, Borok Z. EMT and interstitial lung disease: A mysterious relationship. Curr Opin Pulm Med 2012; 18(5): 517-23.
[88]
Liu T, Warburton RR, Guevara OE, et al. Lack of MK2 Inhibits Myofibroblast Formation and Exacerbates Pulmonary Fibrosis. Am J Respir Cell Mol Biol 2007; 37: 507-17.
[89]
Sousa AM, Liu T, Guevara O, et al. Smooth muscle alpha-actin expression and myofibroblast differentiation by TGFbeta are dependent upon MK2. J Cell Biochem 2007; 100(6): 1581-92.
[90]
Cornell TT, Fleszar A, McHugh W, Blatt NB, Vine AML, Shanley TP. Mitogen-activated protein kinase phosphatase 2, MKP-2, regulates early inflammation in acute lung injury. Am J Physiol Lung Cell Mol Physiol 2012; 303(3): L251-8.
[91]
Aggarwal NR, King LS, D’Alessio FR. Diverse macrophage populations mediate acute lung inflammation and resolution. Am J Physiol Lung Cell Mol Physiol 2014; 306(8): L709-25.
[92]
Cornell TT, Rodenhouse P, Cai Q, Sun L, Shanley TP. Mitogenactivated protein kinase phosphatase 2 regulates the inflammatory response in sepsis. Infect Immun 2010; 78(6): 2868-76.
[93]
Park MS, He Q, Edwards MG, et al. Mitogen-activated protein kinase phosphatase-1 modulates regional effects of injurious mechanical ventilation in rodent lungs. Am J Respir Crit Care Med 2012; 186(1): 72-81.
[94]
Erdem JS, Skaug V, Haugen A, Zienolddiny S. Loss of MKK3 and MK2 copy numbers in non-small cell lung cancer. J Cancer 2016; 7(5): 512-5.
[95]
Liu B, Yang L, Huang B, et al. A functional copy-number variation in MAPKAPK2 predicts risk and prognosis of lung cancer. Am J Hum Genet 2012; 91(2): 384-90.
[96]
Morandell S, Reinhardt HC, Cannell IG, et al. A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo. Cell Reports 2013; 5(4): 868-77.
[97]
Johansen C, Funding AT, Otkjaer K, et al. Protein expression of TNFa in psoriatic skin is regulated at a post-transcriptional level by MAPKAPK-2. J Immunol 2006; 176: 1431-8.
[98]
Ray AL, Castillo EF, Morris KT, et al. Blockade of MK2 is protective in inflammation-associated colorectal cancer development. Int J Cancer 2016; 138: 770-5.
[99]
Oubrie A, Kaptein A. Zwart Ed, et al. Novel ATP competitive MK2 inhibitors with potent biochemical and cell-based activity throughout the series. Bioorg Med Chem Lett 2012; 22: 613-8.
[100]
Qin J, Dhondi P, Huang X, et al. Discovery of a potent dihydrooxadiazole series of non-ATP competitive MK2 (MAPKAPK2) inhibitors. ACS Med Chem Lett 2012; 3: 100-5.
[101]
Xiao D, Zhu X, Sofolarides M, et al. Discovery of a novel series of potent MK2 non-ATP competitive inhibitors usign 1,2-substituted azoles as cis-amide isosteres. Bioorg Med Chem Lett 2014; 24: 3609-13.
[102]
Schlapbach A, Huppertz C. Low molecular-weight MK2 inhibitors: A tough nut to crack! Future Med Chem 2009; 1: 1243-57.
[103]
Hillig RC, Eberspaecher U, Monteclaro F, et al. Structural basis for a high affinity inhibitor bound to protein kinase MK2. J Mol Biol 2007; 369: 735-45.
[104]
Mourey RJ, Burnette BL, Brustkern SJ, et al. A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor α production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. J Pharmacol Exp Ther 2010; 333: 797-807.
[105]
Swinney DC. Biochemical mechanisms of drug action: What does it take for success? Nat Rev Drug Discov 2004; 3: 801-8.
Article Metrics
75
5
2